For CROs & Sponsors
On average, it takes emailing hundreds of feasibility requests to get enough replies. What's worse? For every 100 sites activated, only 20 produce the targeted results. 10% enroll zero patients!
If theres' so much data, why not just select the best sites that can succeed, activate them quickly, and start your trial? Shouldn't it be as easy as an Uber transaction between driver and passenger?
Sound like science fiction? Not anymore.
For Research Sites
Your life blood is new trials but you are drowning in paperwork. Feasibility requests require the SAME data - over and over again and patient pre-screening still seems impossible or expensive. If there's any tech at all, it's fragmented at best. Nothing is tracked.
Why can't sponsors and CROs just bring you the trials that fit your capabilities? Why isn't it easier to match patients to available trials without expensive EMR integrations? Now it's possible.
Join the Ryght Research Network. It's free.
Apps for AI Builders
Ryght has developed an enterprise class, SOC2 compliant, scalable platform and tools that underly a new age of clinical research applications.
Get a 10X lift across the realms of:
- Synthetic, digital twinning
- Protocol navigation
- Study selection
- Medical writing
- Rapid site activation
"By streamlining study selection, feasibility, and patient referrals, the Ryght Research Network will allow us to focus more on advancing patient care and less on administrative burden while running the trials that are most likely to succeed."
David Friedland
M.D, Ph.D., Associate Dean of Clinical Research
Keck School of Medicine of the University of Southern California
“Ryght AI's unique and powerful platform streamlines clinical trials from site selection to activation and enrollment, ultimately speeding up time to market for our biopharma clients.”
Derek Grimes
Executive Vice President and Global Head of Clinical Research
QPS
"We are thrilled to collaborate with Ryght and utilize their GenAI platform to advance our clinical trial processes. Through the application of AI, we aim to further support our biotech clients to develop transformative therapeutics in areas of unmet need.”
Yvonne Lungershausen
CEO
Avance Clinical
"At the University of Adelaide, we are committed to advancing world-class research that addresses many of the challenges faced by society. By working together, we can leverage our collective expertise to develop innovative, responsible and tested solutions for better public health and other critical issues and bring Australia’s AI capabilities up to world-class standards where they belong.”
Professor Mark Hutchinson BSc, PhD
Interim Director of the Institute for Photonics and Advanced Sensing (IPAS)
Adelaide University
Ready to learn more?
